The European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Novartis' Iptacopan for the treatment of adults with paroxysmal nocturnal hemoglobinuria (PNH). This recommendation follows a comprehensive review of clinical data demonstrating the efficacy and safety of Iptacopan in managing this rare, life-threatening blood disorder.

Iptacopan is an oral, first-in-class factor B inhibitor designed to address the underlying cause of PNH by targeting the alternative complement pathway. The EMA's Committee for Medicinal Products for Human Use (CHMP) based its recommendation on results from pivotal Phase III studies, which showed significant improvements in hemoglobin levels and a reduction in the need for blood transfusions among treated patients.

The European Commission will now review the CHMP's opinion, with a final decision on marketing authorization expected in the coming months. If approved, Iptacopan could offer a new therapeutic option for PNH patients across Europe.